Laura Hsieh is the founder of TippingPoint Biosciences, an epigenetic medicine startup that has developed a breakthrough method of drugging the entire chromatin network to create first-in-class epigenetic therapeutics. Laura sits down with Sam Tabone and Brom Rector to discuss:

(1:11) Laura’s background and the history of TippingPoint

(5:30) What is Epigenetics and what is Chromatin?

(10:30) What diseases are driven by Epigenetics and dysfunctional Chromatin?

(14:00) - TippingPoint’s platform and secret sauce

(19:10) - How TippingPoint runs high throughput screening

(23:00) - What is DIPG - the deadly pediatric brain cancer TippingPoint is treating?

(38:30) - What does “disease modifying” mean?

(40:00) - How TippingPoint’s technology can be applied to aging and longevity

(45:00) - What motivates Laura

(49:00) - Could epigenetic medicines be used for human enhancement? How does diet influence Epigenetics?

(55:00) - Academia vs the startup world: does the PhD experience prepare you to be a founder?

(59:00) - Laura’s advice for raising money and pitching VCs

(1:04:00) - Why we invested in TippingPoint

Check out TippingPoint: https://www.tippingpointbiosciences.com/